Holen Sie sich die Stockscreener-App
1.83
1.08%
-0.02
Handel nachbörslich:
1.83
Schlusskurs vom Vortag:
$1.85
Offen:
$1.85
24-Stunden-Volumen:
15,470
Relative Volume:
0.42
Marktkapitalisierung:
$24.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.59M
KGV:
-1.6944
EPS:
-1.08
Netto-Cashflow:
$-19.79M
1W Leistung:
-11.59%
1M Leistung:
-16.82%
6M Leistung:
-58.22%
1J Leistung:
-56.27%
1-Tages-Spanne:
$1.81
$1.94
1-Wochen-Bereich:
$1.81
$2.15
52-Wochen-Spanne:
$1.81
$6.265
Calcimedica Inc Stock (CALC) Company Profile
Firmenname
Calcimedica Inc
Sektor
Branche
Telefon
858-952-5500
Adresse
505 COAST BOULEVARD SOUTH, LA JOLLA
Vergleichen Sie CALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
1.83 | 24.94M | 0 | -13.59M | -19.79M | -1.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Calcimedica Inc Aktie (CALC) Neueste Nachrichten
Analysts Offer Predictions for CalciMedica Q4 Earnings - Defense World
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Corient Private Wealth LLC Buys New Shares in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.81 - Investing.com India
Graybug Vision stock hits 52-week low at $1.81 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $16 target on CalciMedica stock - Investing.com India
CalciMedica Unveils Next-Gen Inflammatory Disease Treatments at Major Healthcare Conference - Stock Titan
CALCIMEDICA Earnings Results: $CALC Reports Quarterly Earnings - Nasdaq
CalciMedica Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Calcimedica Reports 2024 Financial Results And Provides Clinical & Corporate Updates - MarketScreener
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates - PR Newswire
CalciMedica Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Atria Investments Inc Buys 7,509 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Thursday - Defense World
Graybug Vision stock hits 52-week low at $1.83 amid challenges - Investing.com
Head to Head Survey: Rani Therapeutics (NASDAQ:RANI) vs. CalciMedica (NASDAQ:CALC) - The AM Reporter
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora - TipRanks
Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0% - Defense World
Latham & Watkins Advises CalciMedica in Secured Growth Financing - Latham & Watkins LLP
CalciMedica secures $32.5 million credit facility By Investing.com - Investing.com Canada
CalciMedica secures credit facility for up to $32.5M - MSN
CalciMedica Secures Credit Facility For Up To $32.5 Million -March 05, 2025 at 07:44 am EST - Marketscreener.com
CalciMedica secures $32.5 million credit facility - Investing.com India
CalciMedica Secures Credit Facility for Up to $32.5 Million - Finansavisen
CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.95 amid challenges - Investing.com
CalciMedica reports reduced mortality in AKI trial with Auxora - Investing.com
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment - TipRanks
CalciMedica reports reduced mortality in AKI trial with Auxora By Investing.com - Investing.com South Africa
CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial - TipRanks
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Longview News-Journal
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors - Victoria Advocate
CalciMedica announces board changes By Investing.com - Investing.com Australia
CalciMedica appoints new director amid clinical trials By Investing.com - Investing.com Nigeria
CalciMedica announces board changes - Investing.com
CalciMedica appoints new director amid clinical trials - Investing.com
CalciMedica Announces Board Changes and New Appointment - TipRanks
CalciMedica, Inc. (NASDAQ:CALC) Shares Acquired by Geode Capital Management LLC - Defense World
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) - The Eastern Progress Online
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting - The Eastern Progress Online
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Graybug Vision stock hits 52-week low at $2.65 amid market challenges - Investing.com Canada
CalciMedica Announces Presentations at Upcoming Medical Meetings - The Eastern Progress Online
CalciMedica director Fred Middleton buys $12,720 in stock By Investing.com - Investing.com Canada
Finanzdaten der Calcimedica Inc-Aktie (CALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):